Abstract library

48 results for "utility".
#1696 On-going Evaluation of The Clinical Utility of the Health-Related Quality-Of-Life (HRQoL) QLQ-GINET21 Questionnaire (QNR) in the Treatment of Patients (pts) with Gastrointestinal (GI) Neuroendocrine Tumours (NETs). QUALINETS Study
Introduction: Outcome measures reported by pts help to weigh benefit/effect of a therapy on quality of life (QoL), provided that their utility in clinical practice is proved. There are few QoL QNRs for pts with NETs, like QLQ-GINET21, with 21 items assessing muscle/bone pain, body image, information, sexual function, symptoms, social function and disease-related concerns.
Conference: 14th Annual ENETS conference (2017)
Category: ...none of the above
Presenting Author: Dr. Javier Gallego
#538 Cost-Utility of Sunitinib (SU) for Treatment of Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in Scotland and Wales
Introduction: SU is an oral multitargeted tyrosine kinase inhibitor approved in Europe for advanced/metastatic well-differentiated pNET.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Mr Adam Johns
Authors: Johns A, Eatock M, Johal S, ...
#2146 Clinical Utility (CU) Evaluation of the Health-Related Quality-of-Life (HRQoL) QLQ-GINET21 Questionnaire (QNR) in the Treatment of Patients (pts) with Gastrointestinal (GI) Neuroendocrine Tumors (NETs). QUALINETS Study
Introduction: QLQ-GINET21 for pts with GI-NETs covers muscle/bone pain, body image, information, sexual function, symptoms, social function and disease-related concerns.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Guillermo de La Cruz
Authors: Gallego J, Reig O, Sastre J, Garcia I, ...
#1364 Clinical Utility of EpCAM-positive Circulating Tumor Cells in Neuroendocrine Neoplasms Using the CellSearch Platform
Introduction: Circulating tumor cells are captured to predict the prognosis of patients in many types of cancers, but reports are rare on clinical utility and tumor cell shedding in neuroendocrine neoplasms (NENs).
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Bao Xin
Authors: Xin B, Han X, Zhou J, Xu X, ...
Keywords: nen, ctc, cell search
#1582 Utility of Serum Chromogranin B Compared with Chromogranin A as a Biomarker in Japanese Patients with Pancreatic Neuroendocrine Tumors
Introduction: Currently, serum chromogranin A (CgA) is used as a biomarker for pancreatic neuroendocrine tumors (pNET); however, oral use of a proton pump inhibitor (PPI) and renal impairment can affect CgA.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Masami Miki
Authors: Miki M, Ito T, Hijioka M, Kawabe K, ...
#309 The Utility of Alpha Internexin as a Predictive Tissue Biomarker for Proliferation in Gastrointestinal and Pancreatic Neuroendocrine Tumors
Introduction: GEP-NETs are increasing but Ki-67 and CgA provide limited information regarding malignancy. A key unmet need is alternative biomarkers to assess the likelihood of local invasion or metastasis.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Mark Kidd
#899 Evaluation of the Clinical Utility of Plasma Biomarkers in Diagnosis of Neuroendocrine Tumors
Introduction: Neuroendocrine tumors (NETs) are rare cancers that usually develop in the gastroenterohepatic system. Diagnostic workup of these tumors includes measurement of plasma levels of marker peptides. Clinical experience suggests that these markers may be misleading if used before histological or imaging evidence of a NET is available.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Matthew Lunberg-Adams
Authors: Lunberg-Adams M, James A, Perros P, ...
#1222 The Clinical Utility of Blood Derived Gene Cluster Analysis of Neuroendocrine Tumors Using Neoplasia Hallmark Criteria
Introduction: We developed a multianalyte blood (51 transcript) assay (MAAA) for GEP-NETs with a sensitivity (98%) and specificity (97%).
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
Authors: Kidd M, Drozdov I, Modlin I, ...
Keywords: PCR
#2202 Assessment of the Clinical Utility of the NETest in a US Registry-Based Study
Introduction: The clinical relevance of molecular biomarkers in oncology management has been recognized in breast and lung cancer. Current biomarkers in NET disease have limited clinical utility.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
Authors: Liu E, Paulson S, Gulati A, Freudman J, ...
#671 Comparison of the Utility of Biochemical Markers in Predicting the Presence and Severity of Carcinoid Heart Disease
Introduction: Carcinoid heart disease (CHD) is a complication of metastatic neuroendocrine disease and is screened for using echocardiography.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: Dr Rebecca Dobson
Authors: Dobson R, Burgess M, Chadwick C, Vora J, ...